3 results
* To evaluate the long-term efficacy of FCM (using targeted ferritin levels to determine dosing) or oral iron to delay and/or reduce erythropoiesis stimulating agent (ESA) use and/or other anaemia management options in NDD-CKD subjects with iron…
Primary Objectives:• To evaluate the efficacy of intravenous (IV) FCM compared to usual care on exercise capacity.Secondary Objectives:• To evaluate the efficacy of IV FCM compared to usual care on biomarkers for iron deficiency (ID), cardiac…
PART B (FL phase IIb *PARADIGME*):Primary objective:Randomised section of Part B- To evaluate the efficacy of the *40/15* dose regimen (40 mg lilotomab / 15 MBq/kg Betalutin) compared with *100/20* dose regimen (100 mg/m2 lilotomab/ 20 MBq/kg…